title: [Prevalence of antibodies against hepatitis C virus in multitransfused patients].
abstract: We have done a study in order two know the prevalence of anti-hepatitis C virus antibodies in polytransfused patients with hemophilia, leukemia and hemolytic anemia, along with 17 healthy donors, without previous history of transfusions. We analyzed samples from 10 hemophilic patients and 12 from leukemia, lymphoma and hemolytic anemia, all of them had received blood or blood products, at least six months before the study. Using a second generation ELISA, 4 positive sample (3 hemophilic and 1 lymphoma) were detected (10.26%), which represent a prevalence of 30% in the hemophilic group, in contrast with the prevalence detected in other countries. A very significant statistic association was demonstrated, between the positive ELISA, the amount of the transfused product (P < 0.0004) and the type of blood product used for transfusion (crioprecipited, P = 0.000, plasma P = 0.000).
authors.affiliation: Centro Ambulatorio Médico Odontológico de la Universidad de Los Andes, Mérida, Venezuela.
authors.forename: H
authors.initials: H
authors.lastname: Montes
authors.forename: L
authors.initials: L
authors.lastname: Berrueta
authors.forename: J
authors.initials: J
authors.lastname: Cova
authors.forename: S
authors.initials: S
authors.lastname: Salmen
authors.forename: C
authors.initials: C
authors.lastname: Arribas
authors.forename: J
authors.initials: J
authors.lastname: Donis
authors.forename: M
authors.initials: M
authors.lastname: Hernandez
mesh_terms: D000293:Adolescent; D000328:Adult; D000743:Anemia, Hemolytic / Q000628:therapy; D001803:Blood Transfusion; D003430:Cross-Sectional Studies; D006467:Hemophilia A / Q000628:therapy; D006508:Hepatitis Antibodies / Q000097:blood*; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology*; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008297:Male; D015995:Prevalence; D016036:Seroepidemiologic Studies
chemical_list: D006508:Hepatitis Antibodies
vernacular_title: Prevalencia de anticuerpos contra el virus de la hepatitis C en pacientes multitransfundidos.